Agranulocytosis

Summary

Agranulocytosis (MONDO:0001609) is a disease and 7 clinical trials. Top therapeutic interventions include tranexamic acid. A subtype of leukopenia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	agranulocytosis
Mondo ID	MONDO:0001609
MeSH	D000380
DOID	DOID:12987
ICD-10-CM	D70
ICD-11	1913706366
NCIT	C2863
SNOMED CT	417672002
UMLS	C0001824
MedGen	7932
Is cancer (heuristic)	no

Also known as: granulocytopenia

Disease family

This is a subtype of leukopenia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › leukopenia › agranulocytosis

Related subtypes (1): lymphopenia

Subtypes (2): neutropenia, acquired agranulocytosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06707051	PHASE2/PHASE3	COMPLETED	Effect of Tranexamic Acid and Calcium Dobesilate for Bleeding of Endometrial Origin
NCT00005302	Not specified	COMPLETED	Drug Etiology of Aplastic Anemia and Related Dyscrasias
NCT00005307	Not specified	COMPLETED	Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data
NCT00059423	Not specified	COMPLETED	Natural History Study for BEN
NCT01977963	Not specified	UNKNOWN	Genetic Study of Antithyroid Drugs Associated Agranulocytosis
NCT05349383	Not specified	COMPLETED	Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities
NCT06610500	Not specified	COMPLETED	Clozapine Hematological Monitoring Regulatory Compliance Assessment in Psychiatry

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TRANEXAMIC ACID	4	1